Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
17.49
Nov 18 • 3:59 PM ET Dollar change-0.15 Percentage change(-0.85%)
Aftermarket Close
17.49
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Category
Global or ExUS Equities - Industry Sector
Sponsor
Advisor Shares
Fund Family
Index
-
Index Weighting
Active/Passive
Expense
1.00%
Inverse/Leveraged
IPO
Sep 16, 2021
Asset Type
Equities (Stocks)
ETF Type
Bond Type
Average Maturity
Commodity Type
Quant Type
ESG Type
Dividend Type
Structure Type
Growth/Value
Market Cap
Option/Short
Yes / Yes
Tags
Tags
Tags
Tags
Tags
Tags
-
Tags
-
Sector/Theme
Region
SMA20
-11.62%
SMA50
-18.52%
SMA200
-16.13%
Return% 1Y
10.10%
Return% 3Y
15.27%
Return% 5Y
-26.76%
Return% 10Y
Return% SI
Flows% 1M
0.00%
Flows% 3M
-4.25%
Flows% YTD
166.86%
Flows% 1Y
Flows% 3Y
Flows% 5Y
Trades
Total Holdings
29
AUM
38.10M
NAV/sh
52W High
27.02 -35.26%
52W Low
15.63 11.87%
Volatility
4.07% 3.74%
ATR (14)
0.74
RSI (14)
30.38
Beta
1.03
Rel Volume
0.88
Avg Volume
31.97K
Volume
28,025
Perf Week
-12.86%
Perf Month
-17.01%
Perf Quarter
-32.60%
Perf Half Y
-11.98%
Perf YTD
1.86%
Perf Year
-3.16%
Perf 3Y
32.50%
Perf 5Y
-78.67%
Perf 10Y
-
Prev Close
17.64
Price
17.49
Change %
-0.85%
AdvisorShares Psychedelics ETF seeks long-term capital appreciation. The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.